Astellas will close its Seattle stem cell site, acquired in the $102.5 million Universal Cells deal back in 2018, affecting about 55 employees. The shutdown, scheduled by April 2028, is part of its broader effort to consolidate cell and gene therapy research with oncology programs. Meanwhile, GSK is lining up five phase 3 trials for its Hansoh Pharma-partnered B7-H4 antibody-drug conjugate, mocertatug rezetecan, after a 62% overall response rate in earlier ovarian cancer data. Daiichi Sankyo plans to sell its consumer health unit to Suntory Holdings for roughly 246.5 billion yen (about $1.55 billion) over three years, allowing tighter focus on oncology. Takeda has also ended its mRNA discovery agreement with Veritas In Silico on good terms. And AbbVie will pay $30 million upfront, plus up to $715 million in milestones, to Haisco Pharmaceutical for global ex-China rights to two NaV1.8 pain candidates. One more data point: Oricell Therapeutics just raised more than $110 million ahead of a planned IPO.
Taken together, these decisions show leadership across pharma resetting R&D portfolios around oncology, pain, and leaner innovation models. Astellas leaving a U.S. stem cell site reinforces one harsh reality: advanced cell therapy manufacturing stays expensive without nearby commercial returns. Daiichi’s OTC exit fits a decades-long Japanese industry pivot toward higher-margin specialty drugs, cutting ties with legacy consumer products. And at GSK, launching five simultaneous phase 3 ADC programs reveals real conviction at the top, it will stretch trial infrastructure, sure, but matches the company’s drive to rebuild oncology credibility. The 62% response rate makes the case for moving quickly, though ADC safety and payer hurdles remain. Those metrics are increasingly tracked on ClinicalRx.ai.
AbbVie’s $745 million Haisco structure shows how far big pharma will go to lock in differentiated non-opioid pain assets from China. The deal indicates AbbVie is consciously taking early-stage science risk to stay ahead of Vertex’s NaV1.8 franchise. Takeda’s quiet exit from mRNA looks less like retreat and more like focus, swapping platform experimentation for partnerships that tie directly to disease revenue potential. There’s a pattern here. Portfolio optimization has become a management tool as critical as any molecule in the pipeline. And honestly, that’s not a bad thing; discipline makes for better science over time. The larger message across these scattered headlines: capital efficiency now defines R&D success, whatever the therapeutic field.
